type here...
type here...
START FREE TRIAL

Healthcare

Technology & AIHealthcareM&AConsumer & RetailIndustrialsMedia & Entertainment

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

Healthcare Ishan Majumdar -
AbbVie (NYSE:ABBV) just made a bold move—and the stakes are massive. The company agreed to invest $100 billion into U.S. operations over the next...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

Healthcare Ishan Majumdar -
Merck (NYSE:MRK) is making headlines again, this time for reportedly circling Revolution Medicines (NASDAQ:RVMD) in what could be one of the largest biotech acquisitions...
spot_imgspot_img

Niagen NR Patent Acquisition Unlocks Massive Pharma Potential—But There’s a Catch!

Healthcare Ishan Majumdar -
If you blinked, you may have missed one of the more intriguing biotech moves of the year. Niagen Bioscience...

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

Healthcare Ishan Majumdar -
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...

Eli Lilly Adverum Acquisition Could Reshape Gene Therapy!

Healthcare Ishan Majumdar -
Eli Lilly (NYSE:LLY) isn’t slowing down. After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro...

Mirum Bluejay Acquisition Unlocks Rare Disease Gold!

Healthcare Ishan M. -
Mirum Pharmaceuticals (NASDAQ:MIRM) is making big moves. In early December 2025, the company announced its plan to acquire privately...

Novartis Gene Therapy Approval: A New Multi-Billion Dollar Market?

Healthcare Ishan M. -
Novartis just scored a big win with a major Novartis gene therapy approval —and it could reshape the gene...

Johnson & Johnson Halda Acquisition: The $3.05 Billion Gamble!

Healthcare Ishan Majumdar -
Johnson & Johnson just made another big move. The company announced that it will buy Halda Therapeutics for $3.05...
Load more

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

Healthcare Ishan Majumdar -
AbbVie (NYSE:ABBV) just made a bold move—and the stakes are massive. The company agreed to invest $100 billion into...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

Healthcare Ishan Majumdar -
Merck (NYSE:MRK) is making headlines again, this time for reportedly circling Revolution Medicines (NASDAQ:RVMD) in what could be one...

Niagen NR Patent Acquisition Unlocks Massive Pharma Potential—But There’s a Catch!

Healthcare Ishan Majumdar -
If you blinked, you may have missed one of the more intriguing biotech moves of the year. Niagen Bioscience...

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

Healthcare Ishan Majumdar -
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...

Eli Lilly Adverum Acquisition Could Reshape Gene Therapy!

Healthcare Ishan Majumdar -
Eli Lilly (NYSE:LLY) isn’t slowing down. After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro...

Mirum Bluejay Acquisition Unlocks Rare Disease Gold!

Healthcare Ishan M. -
Mirum Pharmaceuticals (NASDAQ:MIRM) is making big moves. In early December 2025, the company announced its plan to acquire privately...

Novartis Gene Therapy Approval: A New Multi-Billion Dollar Market?

Healthcare Ishan M. -
Novartis just scored a big win with a major Novartis gene therapy approval —and it could reshape the gene...

Johnson & Johnson Halda Acquisition: The $3.05 Billion Gamble!

Healthcare Ishan Majumdar -
Johnson & Johnson just made another big move. The company announced that it will buy Halda Therapeutics for $3.05...

Merck Cidara Acquisition: $9.2B Flu Drug Deal to Replace Keytruda

Healthcare Ishan Majumdar -
Merck isn’t waiting around for Keytruda’s patent clock to run out. On November 14, the pharma giant announced its...

Cogent Biosciences’ Cancer Drug Exploded to 136% —Can the Rally Actually Last?

Healthcare Ishan Majumdar -
It’s not every day you see a biotech stock jump 136% before lunch. But that’s exactly what happened with...

Premier Inc. Draws Buyout Interest From Patient Square Capital — Here’s Why This Deal Could Happen

Healthcare Ishan Majumdar -
Premier Inc, a healthcare group purchasing and technology company, has recently become the subject of acquisition interest from private...

GE Healthcare’s Neurology Bet: Can The Icometrix Acquisition Unlock The Alzheimer’s Diagnosis Market?

Healthcare Ishan Majumdar -
GE HealthCare has deepened its push into precision medicine with a strategic agreement to acquire icometrix, a Belgium-based firm...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

0
AbbVie (NYSE:ABBV) just made a bold move—and the stakes...

Alphabet Joins $4 Trillion Club, But Can Gemini Match ChatGPT Health & Copilot?

0
Alphabet (NASDAQ:GOOGL) just closed above a $4 trillion market...

Google AI Shopping Agents vs. ChatGPT: Who Will Own the Future of E-Commerce?

0
Google (NASDAQ:GOOGL) is doubling down on the future of...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

0
Merck (NYSE:MRK) is making headlines again, this time for...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 Baptista Research. All rights reserved.